Sun Pharma extends patient support program for cancer drug in US

Started as part of the imatinib mesylate launch in February 2016, the program is aimed at delivering greater access to the drug to patients

Sun Pharma has announced the extension of its Imatinib Mesylate Savings Card Program in the US beyond July 31, 2016. Started as part of the imatinib mesylate launch in February 2016, the program is aimed at delivering greater access to the drug to patients who have commercial insurance, but whose out-of-pocket cost may exceed an affordable amount. Imatinib mesylate is used in the treatment of multiple cancers

As part of the Imatinib Mesylate savings card program extension, Sun Pharma will continue to offer up to $ 700 reduction on each eligible patient’s initial out-of-pocket cost from their commercial insurer thereby reducing the patient’s out-of-pocket co-payment to as low as $ 10. This benefit will cover a patient’s monthly fills for a 30-day supply of Sun Pharma’s Imatinib Mesylate prescribed for Ph+CML, a form of chronic myeloid leukemia through the extension period.

During the first six months following its launch on February 1, 2016, more than 5,000 prescriptions for Sun Pharma’s imatinib mesylate have been filled by patients utilising this savings card program.

image
Business Standard
177 22
Business Standard

A COMMERCIAL FEATURE

What's this ?

Commercial Feature is a Business Standard Digital Marketing Initiative.

The Editorial/Content team at Business Standard has not contributed to writing or editing these articles.

For further information, please write to assist@bsmail.in

Sun Pharma extends patient support program for cancer drug in US

Started as part of the imatinib mesylate launch in February 2016, the program is aimed at delivering greater access to the drug to patients

Topics

BS B2B Bureau  |  Mumbai 

Sun Pharma has announced the extension of its Imatinib Mesylate Savings Card Program in the US beyond July 31, 2016. Started as part of the imatinib mesylate launch in February 2016, the program is aimed at delivering greater access to the drug to patients who have commercial insurance, but whose out-of-pocket cost may exceed an affordable amount. Imatinib mesylate is used in the treatment of multiple cancers As part of the Imatinib Mesylate savings card program extension, Sun Pharma will continue to offer up to $ 700 reduction on each eligible patient’s initial out-of-pocket ...

RECOMMENDED FOR YOU

Sun Pharma extends patient support program for cancer drug in US

Started as part of the imatinib mesylate launch in February 2016, the program is aimed at delivering greater access to the drug to patients

Started as part of the imatinib mesylate launch in February 2016, the program is aimed at delivering greater access to the drug to patients

Sun Pharma has announced the extension of its Imatinib Mesylate Savings Card Program in the US beyond July 31, 2016. Started as part of the imatinib mesylate launch in February 2016, the program is aimed at delivering greater access to the drug to patients who have commercial insurance, but whose out-of-pocket cost may exceed an affordable amount. Imatinib mesylate is used in the treatment of multiple cancers

As part of the Imatinib Mesylate savings card program extension, Sun Pharma will continue to offer up to $ 700 reduction on each eligible patient’s initial out-of-pocket cost from their commercial insurer thereby reducing the patient’s out-of-pocket co-payment to as low as $ 10. This benefit will cover a patient’s monthly fills for a 30-day supply of Sun Pharma’s Imatinib Mesylate prescribed for Ph+CML, a form of chronic myeloid leukemia through the extension period.

During the first six months following its launch on February 1, 2016, more than 5,000 prescriptions for Sun Pharma’s imatinib mesylate have been filled by patients utilising this savings card program.

image
Business Standard
177 22